BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kampel L, Goldsmith M, Ramishetti S, Veiga N, Rosenblum D, Gutkin A, Chatterjee S, Penn M, Lerman G, Peer D, Muhanna N. Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles. J Control Release 2021;337:378-89. [PMID: 34303750 DOI: 10.1016/j.jconrel.2021.07.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater 2023;:1-19. [PMID: 36691401 DOI: 10.1038/s41578-022-00529-7] [Reference Citation Analysis]
2 Xu Q, Chen Y, Jin Y, Wang Z, Dong H, Kaufmann AM, Albers AE, Qian X. Advanced Nanomedicine for High-Risk HPV-Driven Head and Neck Cancer. Viruses 2022;14. [PMID: 36560828 DOI: 10.3390/v14122824] [Reference Citation Analysis]
3 Gabel M, Knauss A, Fischer D, Neurath MF, Weigmann B. Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies. Int J Mol Sci 2022;23. [PMID: 36430411 DOI: 10.3390/ijms232213929] [Reference Citation Analysis]
4 Nantajit D, Presta L, Sauter T, Tavassoli M. EGFR-induced suppression of HPV E6/E7 is mediated by microRNA-9-5p silencing of BRD4 protein in HPV-positive head and neck squamous cell carcinoma. Cell Death Dis 2022;13:921. [PMID: 36333293 DOI: 10.1038/s41419-022-05269-8] [Reference Citation Analysis]
5 Wu SY, Wu FG, Chen X. Antibody-Incorporated Nanomedicines for Cancer Therapy. Adv Mater 2022;:e2109210. [PMID: 35142395 DOI: 10.1002/adma.202109210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Swart LE, Koekman CA, Seinen CW, Issa H, Rasouli M, Schiffelers RM, Heidenreich O. A Robust Post-Insertion Method for the Preparation of Targeted siRNA LNPs. Int J Pharm 2022;:121741. [PMID: 35421533 DOI: 10.1016/j.ijpharm.2022.121741] [Reference Citation Analysis]
7 Pandey PR, Young KH, Kumar D, Jain N. RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01528-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
8 Salinas-Montalvo AM, Supramaniam A, McMillan NA, Idris A. RNA-based gene targeting therapies for human papillomavirus driven cancers. Cancer Lett 2021;523:111-20. [PMID: 34627949 DOI: 10.1016/j.canlet.2021.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Pan L, Li B, Chen J, Zhang H, Wang X, Shou J, Yang D, Yan X. Nanotechnology-Based Weapons to Combat Human Papillomavirus Infection Associated Diseases. Front Chem 2021;9:798727. [PMID: 34869242 DOI: 10.3389/fchem.2021.798727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]